Upping the Profiling of Chemical Exposures in the Omics Sciences

Why It Matters

Accurate exposure profiling fills a critical data gap, enabling pharmaceutical developers and health researchers to better predict disease risk and drug efficacy across diverse populations.

Key Takeaways

• Panome Bio launches dual workflow exposomics platform
• Discovery workflow screens 32,000 chemicals untargeted
• Targeted workflow quantifies 235 priority compounds
• Exposomics linked to 70‑90% chronic disease risk
• Enables patient stratification and drug trial insights

Pulse Analysis

The rise of exposomics reflects a growing recognition that chemical environments profoundly influence health outcomes. Traditional omics have excelled at mapping genetic and protein landscapes, yet they overlook the myriad synthetic and natural compounds that infiltrate the human body. Panome Bio’s new platform addresses this blind spot by offering both hypothesis‑free discovery and precise targeted analyses, allowing researchers to capture a comprehensive exposure fingerprint in a single workflow.

Technically, the platform’s Discovery arm employs the proprietary MassID™ computational engine to process untargeted LC/MS data against a curated library of 32,000 chemicals, spanning PFAS, pesticides, microplastic metabolites and food additives. Meanwhile, the Targeted service operates within a CLIA‑certified laboratory, delivering quantitative results for 235 high‑priority substances using calibrated reference standards. This dual approach not only broadens analytical coverage but also ensures regulatory‑grade data quality, facilitating seamless integration with Panome’s existing metabolomics, proteomics and transcriptomics pipelines.

For the pharmaceutical industry, the ability to map chemical exposures offers a new lever to explain inter‑patient variability in drug metabolism and therapeutic response. By incorporating exposomic data into trial design, sponsors can stratify participants, identify hidden confounders, and potentially reduce costly trial failures. Beyond drug development, public health agencies stand to benefit from population‑scale exposure surveillance, informing risk assessments and policy decisions aimed at mitigating the 70‑90% disease burden attributed to environmental chemicals.